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Severe pathophysiological changes in critical illness can lead to dramatically altered antimicrobial pharmacokinetics (PK). The
additional effect of obesity on PK potentially increases the challenge for effective dosing. The aim of this prospective study was to
describe the population PK of meropenem for a cohort of critically ill patients, including obese and morbidly obese patients.
Critically ill patients prescribed meropenem were recruited into the following three body mass index (BMI) groups: nonobese
(18.5 to 29.9 kg/m2), obese (30.0 to 39.9 kg/m2), and morbidly obese (>40 kg/m2). Serial plasma samples were taken, and mero-
penem concentrations were determined using a validated chromatographic method. Population PK analysis and Monte Carlo
dosing simulations were undertaken with Pmetrics. Nineteen critically ill patients with different BMI categories were enrolled.
The patients’ mean standard deviation (SD) age, weight, and BMI were 49 15.9 years, 95 22.0 kg, and 33 7.0 kg/m2, re-
spectively. A two-compartment model described the data adequately. The mean SD parameter estimates for the final covariate
model were as follows: clearance (CL), 15.5 6.0 liters/h; volume of distribution in the central compartment (V1), 11.7 5.8
liters; intercompartmental clearance from the central compartment to the peripheral compartment, 25.6 35.1 liters h1; and
intercompartmental clearance from the peripheral compartment to the central compartment, 8.32 12.24 liters h1. Higher
creatinine clearance (CLCR) was associated with a lower probability of target attainment, with BMI having little effect. Although
obesity was found to be associated with an increased V1, dose adjustment based on CLCR appears to be more important than pa-
tient BMI.
The prevalence of obesity worldwide has continued to escalateduring recent decades (1, 2). According to data from different
organizations, more than two-thirds of adults in the United States
are overweight or obese, andmore than one-third are obese (3, 4).
Obesity is thought to be a risk factor for mortality and morbidity
from different types of infection in the intensive care unit (ICU),
as shown for various types of surgical site infections (e.g., after
hysterectomy [5] or spinal surgery [6]), community-acquired
pneumonia (7), and peritonitis in peritoneal dialysis patients (8).
Optimized drug dosing is likely to reduce the burden associated
with infections in these patients, although there are only sparse
data available for clinicians to guide antimicrobial dosing in obese
patients.
Dosing in obese critically ill patients is considered highly chal-
lenging (9, 10). Indeed, the pathophysiological changes associated
with both obesity and critical illness may have additive effects on
altered pharmacokinetics (PK), although there are very limited
published data on this topic (11, 12). The physiological differences
in obese patients include changes in regional blood flow, increased
cardiac output, and increased fat and lean mass (13). These
changes may alter PK and PK/pharmacodynamics (PK/PD) of
antimicrobials, necessitating dosing adjustment. As the preva-
lence of obesity increases, clinicians more frequently confront the
dosing challenges in treating these patients.
Meropenem is a broad-spectrum antimicrobial of the carbap-
enem class which is frequently used as empirical or directed ther-
apy in critically ill patients (14). Meropenem shows time-depen-
dent antibacterial activity. To date, the PK data for meropenem
have not beenwell described for critically ill obese patients. In vitro
and animal infection model data suggest that maintaining un-
bound concentrations above theMIC for 40% of the dosing inter-
val under steady-state PK conditions should be considered amin-
imum exposure target (40% TMIC). It remains unclear whether
standard meropenem dosing regimens achieve this target in crit-
ically ill obese patients.
The aim of this prospective study was to describe the popula-
tion PKofmeropenem for a cohort of critically ill patients, includ-
ing obese and morbidly obese patients.
MATERIALS AND METHODS
Setting. This was an observational PK study using one-interval patient
sampling at a tertiary referral ICU. Ethics approval was obtained from the
local institutional Human Research Ethics Committee (approval no.
HRC/14/QRBW/88). Written informed consent was obtained from all
participants or from their substitute decision-makers.
Study population.The inclusion criteria for this studywere as follows:
(i) age of 18 years, (ii) receiving meropenem (prophylaxis or treat-
ment), and (iii) body mass index (BMI) of 18.5 kg/m2. The exclusion
criteria were as follows: (i) patients on renal replacement therapy, (ii)
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pregnant women, (iii) actively bleeding patients, and (iv) patients with
HIV or hepatitis.
Study protocol. Meropenem was administered according to the in-
tensivist’s decision, with dosage regimens of 500 mg, 1 g, and 2 g. Partic-
ipants were categorized into the following three groups according to BMI:
nonobese (BMI 18.5 to 29.9 kg/m2), obese (BMI 30 to 39.9 kg/m2),
and morbidly obese (BMI of 40 kg/m2). On a single occasion (one
dosing interval), six blood samples were taken from each participant to
determine plasma meropenem concentrations. Blood samples (about 3
ml) were drawn from the participants at the following times: predose and
30 min (end of infusion), 45 min, 1 h, 4 h, and 8 h after dose administra-
tion. Other clinical and demographic data were collected on the day of
plasma sampling, including age, sex, weight, height, and BMI. Clinical
data were also recorded, including SOFA and APACHE II scores, plasma
albumin levels, and serum creatinine concentrations (Scr).
Sample handling, storage, and assay. Collected blood samples were
placed immediately in an ice bath and were centrifuged at 3,000 rpm for
10 min. Plasma samples were stored at 80°C until bioanalysis. Mero-
penem concentrations in plasma were determined by validated high-per-
formance liquid chromatography with UV detection (HPLC-UV) on a
Shimadzu Prominence instrument. Sample analysis was conducted in
batches, with calibration standards and quality controls to which batch
acceptance criteria were applied. Acetonitrile was added to a 100-l ali-
quot of plasma combined with an internal standard (cefotaxime) to pre-
cipitate proteins. Following centrifugation, the supernatant was isolated
and washed with dichloromethane to remove acetonitrile and lipophilic
components. Following centrifugation, the upper layer was isolated for
chromatographic analysis. The stationary phasewas aWaters XBridgeC18
2.1-mm by 50-mm column. The mobile phase was 4% acetonitrile-96%
50 mM phosphate buffer at pH 2.5 delivered isocratically. The eluent was
monitored at 304 nm.
The calibration curvewas linear, with aweighing of 1/x2 over the range
of 0.2 to 100 g/ml. The precision and accuracy at the lower limit of
quantification (LLOQ) were5.9%. The assay was validated against ma-
trix effects (precision and accuracy within 4% at high and low concentra-
tions). The assay’s precision and accuracy were determined for both with-
in-day and between-day comparisons and were within 6.5% at all three
concentrations tested. Bioanalysis techniques were validated and con-
ducted in accordance with the criteria of the U.S. Department of Health
and Human Services, Food and Drug Administration, Center for Drug
Evaluation and Research (CDER) (15).
Population pharmacokinetic modeling. The plasma meropenem
concentrationswere fitted to one- and two-compartmentmodels by using
a nonparametric adaptive grid (NPAG) algorithm within the Pmetrics
package for R (Laboratory of Applied Pharmacokinetics and Bioinfor-
matics, Los Angeles, CA) (16, 17). Clearance (CL) from the central com-
partment and intercompartmental distribution were modeled as first-
order processes.
Demographic and clinical characteristics that were considered biolog-
ically plausible for affecting meropenem PK were tested for inclusion as
covariates. Age, total body weight (TBW), ideal body weight (IBW), lean
body weight (LBW), sex, BMI, BMI category, Scr, creatinine clearance
(CLCR) (estimated by the Cockcroft-Gault equation by separately using
TBW, LBW, and IBW), albumin level, SOFA score, and APACHE II score
were tested. Each of these covariates was plotted against the PK parameter
estimates to assess the level of correlation. Covariates were retained in the
model if they showed a significant improvement in the log likelihood (P
0.05) and/or improved the goodness-of-fit plots.
Model diagnostics. A visual prediction check (VPC) of the observed-
predicted concentration scatterplot, the coefficient of determination of
linear regression of observed-predicted values, and the log likelihood val-
ues for each run were used to evaluate the goodness of fit. Predictive
performance evaluation was based on themeans for both prediction error
(bias) and bias-adjusted squared prediction error (imprecision) for the
population and individual prediction models for the central compart-
ment.
PTA. Monte Carlo simulations (n  1,000) were performed using
Pmetrics software to determine the probability of target attainment (PTA)
with a variety ofMICs forCLCR values andBMI classes.Meropenemdoses
of 500mg given intravenously (i.v.) every 8 h (q8h) as intermittent 30-min
or 3-h prolonged infusions, 1,000 mg given i.v. q8h as intermittent or
prolonged infusions, and 2,000 mg given i.v. q8h as intermittent or pro-
longed infusions were simulated at three different levels of renal function
(CLCR 30, 50, and 150ml/min) and for three BMI categories (nonobese,
obese, and morbidly obese). The PTA for achieving 40% TMIC (mero-
penem plasma concentration remains above the MIC for at least 40% of
the dosing interval) was calculated for the first 24 h of therapy (3 doses
given q8h). Unbound concentrations were calculated using previously
published data on the free fraction of meropenem (98%) (18).
FTA calculation. MIC data for pathogens that are commonly targeted
for treatment with meropenem, i.e., Acinetobacter baumannii and Pseu-
domonas aeruginosa, were obtained from the European Committee for
TABLE 1 Demographic and clinical data for patients in this study
Variablea
Mean value (SD)b
P value
All patients
(n 19)
Nonobese patients
(n 6)
Obese patients
(n 7)
Morbidly obese patients
(n 6)
Age (yr) 49 (15.9) 41 (19.1) 49 (16.2) 58 (7.6) 0.20
Weight (kg) 95 (22.0) 71 (11.6) 103 (6.8) 109 (23.3) 0.01
Ideal body weight (kg) 65 (12.9) 65 (6.7) 72 (6.3) 55 (17.8) 0.05
Lean body weight (kg) 60 (13.1) 53 (7.3) 70 (4.7) 55 (17.7) 0.03
Height (cm) 171 (12.2) 173 (6.0) 177 (7.0) 162 (17.0) 0.07
Sex (male) 11 (58) 2 (33) 7 (100) 2 (33)
BMI (kg/m2) 33 (7.0) 24 (3.4) 33 (2.2) 41 (1.4) 0.01
Scr (mol/liter) 72 (24.0) 62 (26) 89 (20.2) 62 (16.2) 0.05
CG-TBW (ml/min) 151 (62.6) 139 (44.9) 114 (39.3) 206 (66.7) 0.02
CG-IBW (ml/min) 100 (47.5) 135 (59.9) 80 (30.3) 87 (34.2) 0.07
CG-LBW (ml/min) 89 (33.5) 107 (40.9) 77 (27.9) 86 (29.2) 0.29
Albumin level (g/liter) 26 (6.1) 24 (8.1) 28 (5.1) 24 (4.8) 0.40
SOFA score 6 (3.9) 5 (2.8) 6 (4.9) 6 (3.8) 0.80
APACHE II score 20 (6.9) 26 (3.7) 15 (4.2) 20 (6.9) 0.01
a APACHE II, acute physiology and chronic health evaluation; BMI, body mass index; CLCR, measured creatinine clearance; CG-TBW, estimated CLCR calculated using Cockcroft-
Gault equation based on total body weight; CG-IBW, estimated CLCR calculated using Cockcroft-Gault equation based on ideal body weight; CG-LBW, estimated CLCR calculated
using Cockcroft-Gault equation based on lean body weight; Scr, serum creatinine; SOFA, sequential organ failure assessment.
b Data on male gender are presented as numbers (%) of patients.
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Antimicrobial Susceptibility and Testing (EUCAST) database (www
.eucast.org) to determine the fractional target attainment (FTA). The FTA
describes the pharmacodynamic exposure (PTA) ofmeropenem against a
MIC distribution. The FTA threshold was achieved when the value ex-
ceeded 90%. Susceptible MIC distributions for both pathogens (MICs
of 2 mg/liter) were used to determine the FTA for directed therapy.
Additionally, we determined the FTA for the entire MIC distribution (in-
cluding values for susceptible and resistant isolates) to describe dosing
during empirical therapy.
Statistical analysis. Continuous variables are presented as means
(standard deviations [SD]) or medians (interquartile ranges), as appro-
priate. Categorical variables are expressed as absolute numbers and rela-
tive frequencies. The Kolmogorov-Smirnov and Shapiro-Wilk tests were
used to test for normality. One-way analysis of variance (ANOVA) was
used to test for differences in demographic and clinical data between the
BMI categories. Linear regression was used to describe correlations be-
tween patient weight metrics in the 3 BMI categories and the volume of
distribution in the central compartment (V1) and CL values for mero-
penem. All statistical analyses were performed using the statistical soft-
ware package IBM-SPSS Statistics 22.0 (IBM, New York, NY). P values of
0.05 were considered statistically significant.
RESULTS
Demographic and clinical data.Nineteen critically ill patients (11
males) were enrolled in the study, including seven nonobese, six
obese, and six morbidly obese patients. In total, 112 plasma sam-
ples were obtained from these patients. The demographic and
clinical data for the respective BMI categorizations are shown in
Table 1.Only patients’ weights, BMIs, andAPACHE II scoreswere
significantly different between the three BMI categorizations (P
0.05).
Pharmacokinetic model building. The meropenem PK was
best described by a two-compartment linear model with zero-
order input of drug into the central compartment (Fig. 1). Regard-
ing covariates, the Cockcroft-Gault CLCR (CG-CLCR) was tested,
with CG-CLCR calculated using TBW, LBW, and IBW separately.
The CG-CLCR calculated using TBW (normalized to 100 ml/min)
for meropenem CL improved the model fit best. For the mero-
penem volume of distribution in the central compartment (V1),
we applied two categories of BMI (above and below 35 kg/m2), as
this resulted in amore significant improvement in themodel than
using one or three categories. Furthermore, a scaling factor for the
effect of obesity (O) on V1 in the group with BMIs of35 kg/m
2
was included. When these covariates were added, each resulted in
a statistically significant improvement in the log likelihood from
the previous model (P 0.01). The final model was as follows:
TVCL CL CG-CLCR ⁄ 100 (1)
TVV1 V1 BMI ⁄ 300.75 (if BMI is35 kg/m2) (2)
TVV1 VC (BMI/38)
0.75 O (if BMI is35 kg/m2)
(3)
where CG-CLCR is the estimated CLCR calculated using the Cock-
croft-Gault equation, TVCL is the typical value for meropenem
clearance, CL is the population parameter estimate for mero-
penem clearance, TVV1 is the typical value for the meropenem
volume of distribution in the central compartment,V1 is the pop-
ulation parameter estimate for the volume of the central compart-
ment, and O is a scaling factor for obesity.
The mean  SD population pharmacokinetic parameter esti-
mates from the final covariate model are shown in Table 2. The
diagnostic plots to confirm the goodness of fit of the model were
considered acceptable and are shown in Fig. 2. The final covariate
model was then used for Monte Carlo dosing simulations.
Figure 3 shows the observed relationships between V1 and CL
and the mean body weights for the three BMI categories. None of
the measured correlations were statistically significant, although
as described in our model building process, the inclusion of the
effect of BMI on V1 improved the goodness-of-fit plots of the
model.
Dosing simulations. Monte Carlo simulations and PTA for
achieving 40% TMIC for various meropenem doses are presented
FIG 1 Structural PK model for meropenem in critically ill obese and nonobese patients. The model contains the volumes of distribution for the central
compartment (plasma; Vc) and the peripheral compartment (Vp), a rate constant for meropenem distribution from the central to the peripheral compartment
(Kcp), and a rate constant for meropenem distribution from the peripheral to the central compartment (Kpc).
TABLE 2 Parameter estimates for meropenem obtained from the final
covariate two-compartment population pharmacokinetic model
Parametera Mean (SD)
Coefficient of
variation (%) Median
CL (liters/h) 15.50 (5.99) 38.8 14.3
V1 (liters) 11.66 (5.75) 49.3 11.1
kCP (h
1) 25.60 (35.14) 137.2 5.2
kPC (h
1) 8.32 (12.24) 147.1 3.9
O 1.43 (0.46) 32.0 1.5
a CL, population clearance of meropenem; V1, population volume of distribution in the
central compartment; kCP, rate constant for meropenem distribution from the central
to the peripheral compartment; kPC, rate constant for meropenem distribution from
the peripheral to the central compartment; O, scaling factor for obesity.
Meropenem Population PK in Obesity
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in Table 3. The results showed that increasingCLCRwas associated
with a lower PTA for different BMI categories. Furthermore, at the
high CLCR of 150ml/min, the intermittent dosing regimens of 500
mg and 1,000 mg consistently failed to achieve the PK/PD target
for a MIC of 2 mg/liter in almost all BMI groups. In contrast, all
prolonged-infusion doses as well as intermittent infusions of
2,000mg achieved PK/PD targets up to aMICof at least 2mg/liter.
Fractional target attainment. The FTA values for different
simulated dosing regimens and patient BMIs and CLCR for both
directed and empirical coverage ofA. baumannii andP. aeruginosa
FIG 2 Diagnostic plots for the final population pharmacokinetic covariate model. (a) Observed meropenem concentrations versus population predicted
meropenem concentrations (R2 0.814). (b) Observed meropenem concentrations versus individual predicted meropenem concentrations (R2 0.987). (c)
Visual predictive check.
FIG 3 (Left) Relationship of meropenem clearance to the mean (SD) body weights for the BMI categorizations (for clearance versus BMI linear regression, r2
0.4915). (Right) Relationship of volume of distribution of the central compartment (V1) to themean (SD) body weights for the prespecified BMI categorizations
(nonobese, obese, and morbidly obese) (for V1 versus BMI linear regression, r
2 0.4961).
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are shown in Table 4. For empirical therapy, meropenem at 500
mg q8h as intermittent or prolonged infusions failed to achieve
90% coverage ofA. baumannii in all BMI groups at different CLCR
levels. However, as CLCR increased (i.e., CLCR of 50 ml/min),
meropenem given at 500 mg q8h as intermittent or prolonged
infusions also failed to achieve 90% coverage of P. aeruginosa.
Using the higher meropenem dose of 2,000 mg q8h as prolonged
infusions enabled coverage of90% of P. aeruginosa organisms in
all BMI groups at different CLCR levels. However, this higher dose of
meropenemfailed to achieve 90%coverageofA. baumannii in obese
andmorbidly obese patients at CLCR levels of 150ml/min or greater.
For directed therapy, meropenem at 500 mg q8h as intermit-
tent infusions failed to achieve 90% coverage ofA. baumannii and
P. aeruginosa when CLCR was 150 ml/min or higher. Using mero-
penem at 500 mg q8h as prolonged infusions or use of an in-
creased dose (i.e., 1,000 mg and 2,000 mg) enabled coverage of
90% of A. baumannii and P. aeruginosa organisms in all BMI
groups at different CLCR levels.
DISCUSSION
To the best our knowledge, this is the first prospective population
PK study of meropenem in morbidly obese, obese, and nonobese
critically ill patients. We found that BMI was a significant covari-
ate describing meropenem V1, but when BMI was included in
dosing simulations, the presence of different BMIs did not greatly
affect PK/PD target attainment. Importantly, we observed that a
higher CLCR (150 ml/min) was associated with a lower achieve-
ment of PK/PD targets for all patients, while a standard dosing
regimen achieved PK/PD targets for patients with low and normal
kidney function.
As with antibiotic studies, the susceptibility of the pathogen is
of paramount importance to effective drug therapy. In this case,
we evaluated the fractional target attainment againstA. baumannii
and P. aeruginosa with susceptible MIC distributions that are en-
countered as part of directed therapy. We found for almost all
dosing scenarios that meropenem achieved PK/PD targets suc-
cessfully, with the exception of lower doses in the presence of high
CLCR (150ml/min). This suggests thatwhenmeropenem is used
for directed therapy against pathogens with MICs of2 mg/liter,
TABLE 3 Meropenem probabilities of target attainment for different
BMI groups, CLCR values, and dosage regimens and methods of
administrationa
Dose
(mg) q8h
(infusion
interval)
BMI
group
CLCR
(ml/min)
Attainment of PTA for MIC
(mg/liter)
0.5 1 2 4 8 16
500 (II) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
500 (PI) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
1,000 (II) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
1,000 (PI) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
2,000 (II) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
TABLE 3 (Continued)
Dose
(mg) q8h
(infusion
interval)
BMI
group
CLCR
(ml/min)
Attainment of PTA for MIC
(mg/liter)
0.5 1 2 4 8 16
2,000 (PI) Nonobese 30      
50      
150      
Obese 30      
50      
150      
Morbidly
obese
30      
50      
150      
a The target was for the drug concentration to remain above the MIC for 40% of the
dosage interval to achieve bactericidal activity. The meropenem target MIC was chosen
according to the EUCAST breakpoint (2 mg/liter). BMI, body mass index; q8h, three-
times-daily dosing; CLCR, creatinine clearance; II, intermittent infusion; IP, prolonged
infusion.
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TABLE 4 Fractional target attainment for various meropenem dosing regimens, CLCR values, and BMI groups
a
Dose (mg) q8h
(infusion interval) BMI group
CLCR
(ml/min)
FTA (%)
Acinetobacter baumannii Pseudomonas aeruginosa
MIC for directed
therapy
MIC for empirical
therapy
MIC for directed
therapy
MIC for empirical
therapy
500 (II) Nonobese 30 98.93 86.22 99.02 90.92
50 97.86 81.64 98.06 86.44
150 74.31 57.03 77.91 62.90
Obese 30 99.15 85.62 99.25 90.52
50 98.38 81.75 98.54 86.57
150 82.14 62.98 85.20 68.75
Morbidly obese 30 99.34 84.70 99.44 89.58
50 98.69 81.67 98.88 86.46
150 87.65 67.14 90.06 72.61
500 (PI) Nonobese 30 99.93 87.66 99.95 92.29
50 99.89 84.40 99.92 89.28
150 99.61 77.69 99.73 81.98
Obese 30 99.83 86.51 99.87 91.34
50 99.81 83.53 99.86 88.38
150 99.25 76.94 99.48 81.27
Morbidly obese 30 99.72 85.22 99.81 90.03
50 99.67 82.79 99.77 87.58
150 98.60 76.14 99.06 80.57
1,000 (II) Nonobese 30 99.19 94.33 99.24 96.62
50 98.38 88.62 98.49 92.48
150 84.58 67.19 86.56 72.37
Obese 30 99.43 94.12 99.48 96.55
50 99.67 91.84 99.72 95.07
150 90.77 72.44 91.99 77.36
Morbidly obese 30 99.63 92.65 99.67 95.61
50 99.23 88.19 99.32 92.48
150 94.49 75.81 95.18 80.54
1,000 (PI) Nonobese 30 99.98 95.72 99.99 97.82
50 99.97 91.86 99.98 95.29
150 99.97 83.51 99.98 88.28
Obese 30 99.94 94.92 99.96 97.26
50 99.94 90.56 99.96 94.39
150 99.93 82.97 99.95 87.71
Morbidly obese 30 99.95 92.99 99.97 95.94
50 99.95 89.38 99.97 93.52
150 99.91 82.44 99.94 87.14
2,000 (II) Nonobese 30 99.33 96.62 99.38 98.18
50 98.68 94.80 98.75 96.75
150 90.15 75.28 91.19 80.01
Obese 30 99.58 96.75 99.61 98.33
50 99.04 95.27 99.10 97.20
150 94.19 79.69 94.76 84.29
Morbidly obese 30 99.75 96.62 99.77 98.31
50 99.47 95.46 99.52 97.45
150 96.38 82.37 96.72 87.02
2,000 (PI) Nonobese 30 100.00 97.52 100.00 98.99
50 100.00 97.09 100.00 98.73
150 100.00 90.09 100.00 94.14
Obese 30 100.00 97.81 100.00 99.45
50 100.00 97.27 100.00 99.11
150 100.00 89.60 100.00 93.86
Morbidly obese 30 100.00 97.41 100.00 99.17
50 100.00 96.79 100.00 98.77
150 100.00 88.84 100.00 93.23
a BMI, body mass index; CLCR, creatinine clearance; II, intermittent infusion; PI, prolonged infusion.
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dose adjustment is rarely necessary. However, when meropenem
is used as part of empirical therapy before the susceptibilities of the
pathogens are known, depending on local susceptibility patterns
in the case of possible A. baumannii or P. aeruginosa infection,
higher doses and/or use of prolonged infusion should be consid-
ered until the pathogen and susceptibility have been character-
ized.
At higher CLCR levels (150ml/min) in critically ill patients in
all BMI groups, intermittentmeropenem dosing regimens consis-
tently failed to achieve PK/PD targets. This failure could be rem-
edied by adjusting either the dose or the duration of infusion.
Specifically, meropenem at 500 mg or 1,000 mg q8h did not
achieve the PK/PD target for the EUCAST breakpoint for A. bau-
mannii and P. aeruginosa of a MIC of 2 mg/liter. When the doses
were escalated to 2,000 mg q8h, the PK/PD target was achieved.
Similarly, when meropenem was administered as a prolonged in-
fusion (3 h), PK/PD target achievement increased significantly,
even for lower doses of 500mg q8h. This finding is not new for use
ofmeropenem in critically ill patients, but it is novel in the context
of the range of BMIs investigated in this study.
Of all the patient characteristics tested in this study, CLCR had
by far the greatest influence on achievement of PK/PD targets for
meropenem. Even increasing BMI, which has been proposed to
likely be associated with reducedmeropenemPK exposures, had a
far smaller overall effect than CLCR. The BMI effect was described
in our model as being associated with changes in the V1, which
may indicate that altered concentrations are most likely in early
dosing intervals but will be irrelevant thereafter, when dosing
should be performed based only onCLCR. Interestingly, as shown
in Fig. 3, BMI was not well correlated with meropenem CL or
V1. Other weight descriptors were also not correlated, high-
lighting the variable effect that increasing body weight has on
meropenem PK.
A recent retrospective study of 1,400 patients evaluated the
effect of obesity on the unbound plasma concentrations of pipera-
cillin andmeropenem (19). For meropenem, the presence of obe-
sity did not significantly affect unbound concentrations. The au-
thors of that study used logistic regression to demonstrate that
dosing based on CLCR was the strongest predictor of therapeutic
concentrations in critically ill patients, including the obese (odds
ratio [OR], 21.74; 95% confidence interval [CI], 6.02 to 76.92).
Another study retrospectively evaluated the PK of broad-spec-
trum 	-lactam antibiotics, including meropenem, in critically ill
obese and nonobese patients. That study analyzed routine thera-
peutic drug monitoring (TDM) data from 17 obese (BMI of30
kg/m2) and 17 nonobese (BMI of25 kg/m2) patients and found
that meropenem CL values were not significantly different be-
tween the critically ill obese and nonobese patients (20). However,
the total volume of distribution was nonsignificantly higher in the
obese group (40.0 liters versus 27.9 liters; P 0.10). The authors
concluded that TDM should be performed routinely for obese
critically ill patients.
In a small prospective PK study of 9morbidly obese critically ill
patients (mean  SD BMI, 54.7  8.6 kg/m2), Cheatham et al.
(21) also found that CL values for meropenem were similar be-
tween the enrolled morbidly obese patients and previously pub-
lished data on nonobese patients. Like the present study and that
of Hites et al. (20), the total volume of distribution (in that study
described as the volume of distribution at steady state [Vss]) was
numerically larger in the morbidly obese group (37.8 liters versus
21.7 liters). It was suggested that standard dosing regimens of
meropenem can provided adequate PK/PD target attainment for
susceptible pathogens (MICs of2mg/liter). The data from these
previous studies generally support our results, with BMI, often
described as an obesity category, affecting V but not CL and hav-
ing little effect on achievement of PK/PD targets.
This analysis has some limitations. First, estimation of CLCR by
using the Cockcroft-Gault method is known to be suboptimal for
critically ill patients. However, it is still commonly used clinically,
although 8- or 24-h urinary CLCR measurements should be used
where possible for increased accuracy (22–24). Given that we did
not have urinary CLCR values, we used Cockcroft-Gault CLCR val-
ues in ourmodeling process and found that they greatly improved
the model, and thus they were retained. Notably, the weight de-
scriptor for CG-CLCR was TBW, and clinicians should use this
weight metric in calculating CG-CLCR for meropenem dosing.
Second, although this is the largest prospective PK study of its type
for meropenem, the sample size in this study is not sufficient for
quantification of the effect of meropenem exposure on patient
outcomes. Third, in the morbidly obese group (n 6), the higher
BMI was associated predominantly with a lower patient height
rather than a higher weight. It is possible that a high BMI due to
high weight may affect the PK of meropenem in a different way.
Furthermore, increasing the sample size may also have helped to
define additional patient factors associated with altered PK and to
include a wider range of heights and weights, although these may
not be clinically relevant.
Conclusions. In summary, this analysis presents the first pop-
ulation pharmacokinetic study of meropenem in critically ill pa-
tients with three different BMI categories. BMI appears to have a
minimal effect on PK/PD target attainment in critically ill pa-
tients, while increasing CG-CLCR (calculated using TBW) values
were strongly associated with lower PK/PD target attainment
rates. Higher doses or prolonged infusions should be applied for
pathogens that have a higher MIC and/or for critically ill obese
and nonobese patients with high CLCR values. TDM of mero-
penem should be used where possible to help to optimize mero-
penem dosing regimens accordingly.
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